Figure 2 |. MPP8 is dispensable for hematopoiesis but required for AML development in vivo.

a, Schematic of the MPP8 constitutive and conditional KO mouse models. b,c, Frequencies of hematopoietic stem and progenitor cell populations in bone marrow of MPP8 constitutive heterozygous (MPP8^+/−) or homozygous (MPP8^−/−) KO (b), or conditional heterozygous or homozygous KO by Mx1-Cre two weeks post-pIpC (c). Results are mean ± SD (N = 5 mice per genotype) and analyzed by a two-way ANOVA with Tukey’s test. d, Schematic of the leukemia initiation experiments. e,f, Kaplan-Meier survival curves of recipient mice engrafted with cells transduced with AE9a (e) or MLL-AF9 (f). N = 7 WT and 9 MPP8^−/− mice. P values by a log-rank Mantel-Cox test. Quantification of leukemia burden by % of GFP⁺ leukemia cells in PB, BM and spleen at day 68 (AE9a) or day 41 (MLL-AF9) post-transplantation is shown, respectively. Results are mean ± SEM (N = 5 mice per group) and analyzed by a two-way ANOVA with Bonferroni’s multiple comparison test. g, Schematic of the leukemia maintenance experiments. h,i, Kaplan-Meier survival curves of recipient mice engrafted with cells transduced with AE9a (h) or MLL-AF9 (i). N = 7 (h) or 8 (i) WT and 9 Mx1-Cre⁺; MPP8^f/f mice. P values by a log-rank Mantel-Cox test. Leukemia burden at day 95 (AE9a) or day 62 (MLL-AF9) post-transplantation is shown. Results are mean ± SEM (N = 5 mice per group) and analyzed by a two-way ANOVA with Bonferroni’s test.